No Data
No Data
Shareholders in China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Are in the Red If They Invested Three Years Ago
CR Boya's H1 Attributable Profit Falls 3% as Revenue Plunges 42%
China Resources Boya Bio-pharmaceutical Group: Summary of Half-Year Report in 2024.
China Resources Boya Bio-pharmaceutical Group: Half-year report for the year 2024.
China Resources Boya Bio-Pharmaceutical Group (300294.SZ): Net income in the first half of the year decreased by 3.05% to 0.316 billion yuan. It plans to distribute a dividend of 1.6 yuan per 10 shares.
China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced its 2024 semi-annual report, with operating revenue of 0.896 billion yuan, a year-on-year decrease of 41.87%; net income attributable to shareholders of listed companies of 0.316 billion yuan, a year-on-year decrease of 3.05%; net income attributable to shareholders of listed companies after deducting non-recurring items of 0.259 billion yuan, a year-on-year increase of 0.57%; basic earnings per share of 0.63 yuan; proposed cash dividend of 1.60 yuan per 10 shares to all shareholders (including tax).
Sinolink Securities: Further consolidation of the blood product industry through external mergers and acquisitions and product diversification.
Referring to the development process of leading overseas blood product companies, external mergers and acquisitions, new product development, and efficiency improvement are three important development routes. In recent years, domestic blood product industry mergers and acquisitions have continued to take place, and the concentration of the industry has shown a further upward trend.
No Data
No Data